Biotechnology

SL PHARM

SL PHARM released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 164.89 M, actual EPS CNY -0.4874

SL PHARM released FY2026 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 136.84 M, actual EPS CNY -0.08

SL PHARM released FY2025 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 623.64 M (forecast CNY 1.373 B), actual EPS CNY -0.34

SL PHARM to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

SL PHARM to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 1.373 B

SL PHARM released FY2025 9 Months Earnings on October 26 After-Market BJT, actual revenue CNY 458.75 M, actual EPS CNY 0.1452

SL PHARM released FY2025 Q3 earnings on October 26 After-Market BJT, actual revenue CNY 153.89 M, actual EPS CNY 0.0188

SL PHARM to Release FY2025 Q3 Earnings on October 27 After-Market (BJT)

SL PHARM released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), actual revenue CNY 304.86 M, actual EPS CNY 0.12

SL PHARM released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 135.96 M, actual EPS CNY 0.0864

SL PHARM to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Shuanglu Pharmaceutical Expected Net Profit Growth of 237.95%-356.24% in H1 2025

Sinobioway's ESG Rating Dropped from BB to B

Double 鹭 Pharma Secretary Responds to Investors' Questions on Products and Investments

Bioland Pharma Adds Influenza Concept

Beijing Shuanglu Plans to Reduce Holdings in Xinghao Pharmaceutical by 1.51%

Sulan Pharmaceuticals Reports Net Profit Decline in 2024 and Plans Dividend Distribution

SL PHARM released FY2024 Q4 earnings on April 21 After-Market (BJT), actual revenue CNY 119.86 M (forecast CNY 252 M), actual EPS CNY -0.0497

SL PHARM released FY2024 earnings on April 21 After-Market (BJT), actual revenue CNY 660.42 M (forecast CNY 1.184 B), actual EPS CNY -0.07

SL PHARM released FY2025 Q1 earnings on April 21 After-Market BJT, actual revenue CNY 168.9 M, actual EPS CNY 0.04

512290

002038

002923

Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

Wallstreetcn

Guotai CSI Bio-medicine ETF

Rundu Pharma

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

RemeGen

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

NEPTUNUS

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Sunshine Guojian Pharmaceutical

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

HITECK

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Cosunter

000963

On January 31, according to the National Healthcare Security Administration, the new national medical insurance drug list will be fully implemented in Guangxi starting from January 1, 2026. In this adjustment of the list, the National Healthcare Security Administration has included "Deferasirox Tablets" in the national medical insurance drug list through negotiations, effectively addressing the medical needs of patients with thalassemia and reducing the medication burden on insured patients' families. Before being included in medical insurance, urban and rural residents' patients incurred nearly 3,000 yuan in out-of-pocket expenses per month for treatment at designated institutions in cities and counties. After being included in medical insurance, the negotiated price reduction combined with medical insurance reimbursement means that individuals only need to pay one-tenth of the original amount

36Kr

HUADONG MEDICINE

Hwabao WP CSI Pharmaceuticals ETF

CISEN

huahaipharm

Allmed Medical

ChinaAMC CSI Biotechnology Theme ETF

National Healthcare Security Administration: Key drug "Deferasirox" for treating "thalassemia" included in medical insurance

On November 3rd, SL PHARM stated on the interactive platform that the company's GLP-1 long-acting product is currently organizing materials in preparation for submission

Zhitong

SL PHARM: GLP-1 long-acting products are organizing materials in preparation for reporting

According to the Zhitong Finance APP, SL PHARM released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 459 million yuan, a year-on-year decrease of 15.13%. The net profit attributable to shareholders of the listed company was 141 million yuan, a year-on-year increase of 943.10%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.3349 million yuan, a year-on-year decrease of 62.39%

SL PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 141 million yuan, a year-on-year increase of 943.10%

SL PHARM announced that its associate company Changfeng Pharmaceutical is expected to be listed in Hong Kong on October 8, 2025, with a stock code and a global offering of 41.198 million shares at an issue price of HKD 14.75. SL PHARM holds a 3.68% stake in Changfeng Pharmaceutical, with a lock-up period of 12 months. The listing is expected to have a positive impact on SL PHARM's financial and operational results, and investors should be aware of the risks

SL PHARM: The invested company Changfeng Pharmaceutical plans to go public in Hong Kong on October 8

SL PHARM announced that director and board secretary Liang Shujie holds 1.5008 million shares, accounting for 0.1461%; plans to reduce holdings by no more than 375,200 shares, accounting for 0.0365%, through centralized bidding within three months after the announcement date, with no reduction during the window period, and the reduction price will be determined at market price

SL PHARM: Liang Shujie plans to reduce her holdings by 0.0365%

According to the Zhitong Finance APP, SL PHARM released its semi-annual report for 2025, showing an operating income of 305 million yuan, a year-on-year decrease of 22.24%. The net profit attributable to shareholders of the listed company was 121 million yuan, a year-on-year increase of 309.08%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 26.044 million yuan, a year-on-year decrease of 78.42%. The basic earnings per share were 0.12 yuan

SL PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 121 million yuan, an increase of 309.08%

SL PHARM announced that it expects a net profit of 100 million to 135 million yuan in the first half of 2025, an increase of 237.95% to 356.24% compared to 29.59 million yuan in the same period last year

SL PHARM: Expected net profit in the first half of the year to increase by 237.95%-356.24% year-on-year

Xinghao Pharmaceutical announced that its shareholder Beijing SL PHARM Co., Ltd., holding more than 5% of the shares, plans to reduce its holdings by no more than 1.85 million shares, accounting for 1.51% of the company's total share capital. The reduction will be conducted through centralized bidding or block trading, and the reduction period will be within three months after 30 trading days from the date of the announcement. The reduction price will be determined based on the secondary market price at the time of the reduction, and the reason for the reduction is funding needs

Xinghao Pharmaceutical: SL PHARM plans to reduce its holdings of no more than 1.51% of the company's shares

According to the Zhitong Finance APP, SL PHARM released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 169 million yuan, a year-on-year decrease of 31.10%. The net profit attributable to shareholders of the listed company was 45.9684 million yuan, a year-on-year decrease of 34.46%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 21.1418 million yuan, a year-on-year decrease of 79.19%

SL PHARM released its first-quarter performance, with a net profit attributable to the parent company of 45.9684 million yuan, a year-on-year decrease of 34.46%

SL PHARM(002038.SZ)